Trial Profile
Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation; Polypoidal choroidal vasculopathy
- Focus Adverse reactions
- Acronyms RIVAL Trial
- 15 May 2014 New trial record